suramin

Phase 3Small molecule

EEastern Cooperative Oncology Group

suramin is one of 284 small molecule programs targeting Prostate Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

283

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CarcinomaActive, not recruiting

Transitional Cell CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Bladder CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

AutismActive, not recruiting

Prostate CarcinomaPhase 2

Active, not recruiting

Transitional Cell CarcinomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Bladder CancerPhase 1

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

AutismPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

suramin

EEastern Cooperative Oncology Group

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Lexiscan

Astellas

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00066768·24 enrolled

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006929·82 enrolled

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01671332·80 enrolled

Prostate Cancer2 trials

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002881

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002723·390 enrolled

Glioblastoma Multiforme1 trial

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00004073·54 enrolled

Prostate Carcinoma1 trial

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001266·70 enrolled

Transitional Cell Carcinoma1 trial

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001381·18 enrolled

9 more indications

Stage III1 trial

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00002921·13 enrolled

Fluorouracil1 trial

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00083109·36 enrolled

Bladder Cancer1 trial

Suramin in Treating Patients With Recurrent Bladder Cancer

Completed·CCancer Research UK·Phase 1·NCT00006476·15 enrolled

Multiple Myeloma1 trial

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Completed·UUniversity of Arkansas·Phase 2·NCT00002652

Breast Cancer1 trial

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00054028·31 enrolled

Patients With Advanced Solid Tumors1 trial

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00003038

Autism1 trial

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Completed·UUniversity of California, San Diego·Phase 1/2·NCT02508259·10 enrolled

Primary Brain Tumor1 trial

Suramin in Treating Patients With Recurrent Primary Brain Tumors

Completed·EEmory University·Phase 2·NCT00002639

Unspecified1 trial

Study of Suramin in Subjects With Furosemide-Resistant AKI

Unknown status·RRediscovery Life Sciences·Phase 2·NCT04496596·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for suramin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — suramin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for suramin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

suramin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Prostate Cancer2 trials

Glioblastoma Multiforme1 trial

Prostate Carcinoma1 trial

Transitional Cell Carcinoma1 trial

Stage III1 trial

Fluorouracil1 trial

Bladder Cancer1 trial

Multiple Myeloma1 trial

Breast Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Autism1 trial

Primary Brain Tumor1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News